Breast Cancer
Left Breast Carcinoma
Female, 45 years
Patient Internal ID: 289422365
ICD-10 code
C50.8 Malignant Neoplasm of Overlapping Sites of Breast
Diagnosis (Incl. Metastases/Stage) and Year
September 2020
Carcinoma of the Left Breast cT2N2M0, G2 ER(-), PR(-), HER2(-), Ki67-75%, stage IIIA, BRCA2 Gene Mutation.
Post Neoadjuvant Chemotherapy (2021-03) and Bilateral Mastectomy ypT0 N1a M0 LVI-1 R0.
Previous Treatment
Surgery, Chemotherapy (Paclitaxel, Carboplatin), Chemotherapy (Capecitabine), Radiation Therapy.
Prognosis and Survival Expectation
The estimated Five-Year Triple-Negative Breast Cancer survival rate with Regional Spread is 65.4% (SEER).
Treatment Provided
Autologous DCV (5 doses) and CIK (4 doses) over a period of 9 months. Additionally, the patient received Umbilical Cord Blood Derived NK Cells (4 doses), Immunostimulation of Interferon (IFN) β and Tumor Necrosis Factor (TNF).
Patient Survival/Condition and Year
Date of Review: 15/10/2023
The patient is alive (now 37 months since diagnosis), without disease progression. The patient continues follow-up care every 6 months. It can be concluded that the addition of Immunotherapy, alongside, Surgery, Chemotherapies and Radiation Therapy, has benefited the patient with stable disease and disease control.
